SUMMARY Serum lipoprotein profiles were investigated in 108 male patients with primary gout before treatment to elucidate the prevalence of each individual phenotype of coexisting hyperlipoproteinaemia and pathogenic factors responsible for it. The mean serum triglyceride (TG) and total cholesterol (TC) levels in the patients with gout were 2-10±0-14 mmol/l and 5.26±0.10 mmol/l (mean±SEM) respectively, which were significantly higher (p<0-01 and p<O0O5 respectively) than the levels in age matched controls without gout (1.30±0.07 mmol/I and 4-77±0-08 mmol/l respectively). Serum high density lipoprotein cholesterol (HDL-C) values were slightly decreased in patients with gout compared with controls (1P24±0-08 mmolUl v 1.40±0*03 mmol/l, p<005). Hyperlipoproteinaemia was seen in 61 patients (56%), of whom patients with type Ila, Ilb, and IV hyperlipoproteinaemia formed 13, 15, and 69% respectively.
H,vperlipoproteinaemia in primary gout 309 investigators,'-12 but the significance of serum lipoproteins, the form in which lipids circulate, has not been well documented in primary gout.
Moreover, the mechanism of development of hyperlipidaemia in primary gout is controversial. A number of investigations suggested that it might be due to excessive alcohol intake and obesity." 13 However, no direct evidence supporting this has been presented. In addition, previous studies have dealt with small or heterogeneous populations.'2 14 In the present study we used a relatively large and homogeneous group of 108 untreated patients with primary gout, whose lipoprotein phenotypes were identified by means of polyacrylamide gel disc electrophoresis, and tried to clarify whether hyperlipoproteinaemia in primary gout is consequent upon essential factors or secondary to alcohol intake or obesity.
Subjects and methods

SUBJECTS
The subjects used in this study were 108 male patients with primary gout, 877 normouricaemic males with primary hyperlipoproteinaemia, and 92 normouricaemic healthy male controls. The patients with gout were selected from the population of 198 patients with primary gout referred to our clinic. They had received no medication for hyperuricaemia or hyperlipoproteinaemia for at least six months before the study. Of 
Results
The clinical features of the subjects are shown in Table 1 . There was no significant difference between the patients with primary gout and the normal controls with respect to age, obesity index, alcohol intake, or smoking. The mean SUA level was 0-54±0-01 mmol/l (mean±SEM) in the untreated gouty patients (gout group). The serum TG and TC values were higher in the gout group than in the control group (p<0-01 and p<0-05 respectively).
The HDL-C levels were slightly but significantly decreased in the gout group (p<005). Of the 108 Values are expressed as percentages. Numbers of the subjects are given in parentheses.
*p<0-01 (v primary HLP). The changes in serum lipoprotein profiles during treatment with antihyperuricaemic agents were also investigated. We were able to perform a follow up study in 81 patients. The follow up periods ranged from one to 58 months (mean±SEM 12±1). Thirty one of these patients were treated with allopurinol, 25 with probenecid, and the rest with a combination of both drugs. On medication the SUA level was significantly decreased from the baseline level of 0-54±0-01 mmol/l to 0-34±0-01 mmol/l (p<0001).
In contrast, there was no significant change in serum TG, TC, and HDL-C values during the treatment. The changes in hyperlipoproteinaemic phenotype are summarised in Table 4 . Of the 48 hyperlipoproteinaemic cases followed up, the phenotype changed from one of Ila, Ilb, and IV to another in eight cases during the treatment. Two patients with type V hyperlipoproteinaemia changed to type IV after the cessation of alcohol intake. Forty six patients showed no change in phenotype.
Discussion
This study showed raised serum TC and TG levels, decreased HDL-C values, and a high frequency of type IV hyperlipoproteinaemia in patients with primary gout. There is considerable evidence to support the association of gout with hypertriglyceridaemia. Several studies have suggested that the hypertriglyceridaemia might be caused by alcohol intake or obesity, or both, which are common in gouty patients. 1 13 However, there has been no adequate evidence of the necessity of these factors for the development of hypertriglyceridaemia in patients with primary gout. The present study showed that alcohol intake did affect serum TG levels but was not essential for the occurrence of hypertriglyceridaemia. In addition, adiposity was not an independent predictor of a rise of serum TG concentration or the occurrence of hypertriglyceridaemia in patients with primary gout, after adjustment for alcohol ingestion, SUA, BUN, and smoking. Although Naito and Mackenzie'2 also noticed that the serum TG concentration was higher in gouty patients having no history of drinking than that in controls, they investigated only 30 patients, including individuals on medication. Raised levels of serum TG in non-drinking gouty patients were also reported by Nishida et al,20 who, however, did not consider the influence of obesity. In contrast, we ability of its phenotype (Ila, IIb, and IV).
In conclusion, we propose that hyperlipoproteinaemia in primary gout is unlikely to be secondary to excess alcohol intake or obesity, or both, and, instead, it may be associated with essential factors, at least in some patients with primary gout. In addition, the hyperlipoproteinaemia in primary gout may be due to the overproduction of TG rich lipoproteins rather than to the impairment of their catabolism. Our data suggested that it could be attributed to combined hyperlipidaemia in some gouty patients, though the detailed mechanism still remains to be elucidated.
